Indivior First Quarter 2025 Earnings: Beats Expectations

Indivior (LON:INDV) First Quarter 2025 Results

Key Financial Results

• Revenue: US$266.0m (down 6.3% from 1Q 2024).
• Net income: US$47.0m (flat on 1Q 2024).
• Profit margin: 18% (up from 17% in 1Q 2024).
• EPS: US$0.38 (up from US$0.35 in 1Q 2024).

Our free stock report includes 3 warning signs investors should be aware of before investing in Indivior. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Indivior Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 77%.

Looking ahead, revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's shares are up 18% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Indivior has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.